Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial. J of Skin 2024, 8 (6), s446. https://doi.org/10.25251/skin.8.supp.446.